Article Details - Overview
This activity is part of PER's Integrated Oncology Learning Series:
A Focus on Chronic Lymphocytic Leukemia
Advances in Frontline Therapy for Chronic Lymphocytic Leukemia
Oncology Briefings Vol. 7, No. 2
Release Date: August 25, 2009
Expiration Date: August 25, 2010
Publication Overview
Authors
Medical writer: Sabeeha Muneer, PhD; Reviewed by: Emili Montserrat, MD
Overview and Purpose
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world, with approximately 15,000 new cases diagnosed in the United States annually. For frontline management of patients with CLL, current guidelines recommend the use of purine analogues and alkylating agents either alone or in combination. Although these chemotherapy approaches yield a relatively high proportion of responses, they have been unsuccessful in producing sustained and durable responses. This past decade has witnessed the introduction of new treatment strategies, including the use of monoclonal antibodies (MoAbs) in combination with chemotherapy regimens, that have changed the therapeutic landscape for CLL and have yielded improved response rates and prolongation of disease-free survival. In an effort to further improve clinical outcomes and deepen achieved remissions, new MoAbs against novel molecular targets, cytotoxic agents, and other biologic agents are being clinically tested as frontline therapy for patients with CLL.
The purpose of this activity is to update physicians on emerging treatment strategies for the management of patients with previously untreated CLL.
Target Audience
Target Audience
This educational activity is intended for medical oncologists and hematologists involved in the care of patients with CLL. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.
Learning Objectives
Upon completion of this educational activity, you should be able to:
- Discuss the use of purine analogue–based chemoimmunotherapy regimens in patients with previously untreated CLL
- Describe the characteristics of second- and third-generation anti-CD20 MoAbs
- Assess the use of bifunctional alkylators and other treatment strategies in patients with previously untreated CLL
Instructions for Participation
- Read the following information before entering the educational activity.
- Complete the Pretest.
- Study the educational activity.
- Complete the Posttest.
- Answer the evaluation questions.
- After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.
You will be permitted 2 attempts to successfully complete the Posttest.
The tests and evaluation must be completed by August 25, 2010, in order for you to receive your certificate.
CME credit will be granted for only 1 form of participation, either online or via the printed publication.
You will be asked to login
or create an account.